TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20

Oncogene

Volumn 32, Issue 16, 2013, Pages 2096-2106

  Kawabata, K C ^a   Ehata, S ^a   Komuro, A ^a   Takeuchi, K ^b   Miyazono, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

apoptosis; B cell lymphoma; MS4A1 CD20; rituximab; TGF

Indexed keywords

CD20 ANTIGEN; OLIGONUCLEOTIDE; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CELL LINE, TUMOR; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

HUMAN HERPESVIRUS 4;

EID: 84876687780     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.219     Document Type: Article

References (43)

1. Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696-702.
2. Jaffe E. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology (Am Soc Hematol Educ Program). 2009; 523-531.
3. Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991; 77: 1516-1526.
4. Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, Amato T et al. Immu-noglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106: 1031-1036.
5. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
6. Guikema JE, de Boer C, Haralambieva E, Smit LA, van Noesel CJ, Schuuring E et al. IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination. Genes Chromosomes Cancer 2006; 45: 808-819.
7. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51.
8. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-b family signalling. Nature 2003; 425: 577-584.
9. Massagué J. TGF-b in cancer. Cell 2008; 134: 215-230.
10. Bierie B, Moses HL. Tumour microenvironment: TGFb: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
11. Ikushima H, Miyazono K. TGF-b signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-b. Cell Tissue Res 2012; 347: 37-49.
12. Lin HK, Bergmann S, Pandolfi PP. Deregulated TGF-b signaling in leukemogenesis. Oncogene 2005; 24: 5693-5700.
13. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004; 351: 552-559.
14. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-b signalling. Nature 2004; 431: 205-211.
15. Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y. Transforming growth factor-b-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res 1998; 242: 244-254.
16. Spender LC, Inman GJ. TGF-b induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1. J Biol Chem 2009; 284: 1435-1442.
17. Derynck R, Akhurst RJ, Balmain A. TGF-b signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
18. Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y. Transforming growth factor-b-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res 1998; 242: 244-254.
19. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-1433.
20. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44: 15150-15158.
21. van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009; 67: 251-259.
22. Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci 2010; 101: 201-209.
23. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 1103-1108.
24. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99: 3256-5362.
25. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009; 15: 6582-6594.
26. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K et al. A transforming growth factor b receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995; 55: 5545-5547.
27. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15: 4674-4679.
28. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor b signaling. Blood 2001; 97: 2815-2822.
29. Goyama S, Kurokawa M. Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 2009; 100: 990-995.
30. Inman GJ, Allday MJ. Resistance to TGF-b1 correlates with a reduction of TGF-b type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 2000; 81: 1567-1578.
31. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of 'crippled' germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106: 4339-4344.
32. Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T et al. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 2009; 390: 48-53.
33. Daniels I, Turzanski J, Haynes AP. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. Br J Haematol 2008; 142: 394-403.
34. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007; 26: 6184-6193.
35. Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009; 50: 873-885.
36. Hoshino Y, Katsuno Y, Ehata S, Miyazono K. Autocrine TGF-b protects breast cancer cells from apoptosis through reduction of BH3-only protein, Bim. J Biochem 2011; 149: 55-65.
37. Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M et al. Transforming growth factor-b promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res 2007; 67: 9694-9703.
38. Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y et al. Transforming growth factor-b decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 2011; 30: 1693-1705.
39. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K et al. Ki26894, a novel transforming growth factor-b type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98: 127-133.
40. Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M et al. Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor-b signaling. Mol Cell Biol 2009; 29: 172-186.
41. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673-683.
42. Gopal AK, Pagel JM, Hedin N, Press OW. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004; 103: 3516-3520.
43. Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110: 4037-4046.